Lenalidomide plus rituximab as initial treatment for mantle-cell Lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Mantle-Cell
  • Thalidomide

abstract

  • Combination biologic therapy consisting of lenalidomide plus rituximab was active as initial therapy for mantle-cell lymphoma. (Funded by Celgene and Weill Cornell Medical College; ClinicalTrials.gov number, NCT01472562.).

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4710541

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1505237

PubMed ID

  • 26535512

Additional Document Info

start page

  • 1835

end page

  • 44

volume

  • 373

number

  • 19